z-logo
Premium
Second case of CML with aberrant BCR‐ABL fusion transcript (e8/a2) with insertion of an inverted ABL intron 1b sequence
Author(s) -
Sugimoto Takeshi,
Ijima Kentaro,
Hisatomi Hisashi,
Murayama Tohru,
Mizuno Ishikazu,
Hato Akio,
Imoto Shion,
Nishimura Ryuichiro,
Koizumi Tamio
Publication year - 2004
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20138
Subject(s) - exon , fusion transcript , chronic myelogenous leukemia , abl , biology , intron , breakpoint cluster region , microbiology and biotechnology , fusion gene , cancer research , genetics , leukemia , gene , receptor , tyrosine kinase
We found a case of Ph‐positive chronic myelogenous leukemia (CML) patient with an atypical BCR‐ABL transcript that was undetectable by a routine reverse transcription polymerase chain reaction (RT‐PCR) for major BCR‐ABL. Additional RT‐PCR and sequence analyses have demonstrated that the aberrant transcript consists of a fusion of BCR exon 8 (e8) and ABL exon 2 (a2) with an insertion of a 55‐bp inverted sequence of intron 1b between them. The nucleotide sequences of the aberrant transcript were identical to those of a previously reported CML patient. These are the only two CML cases in the literature with identical aberrant BCR‐ABL transcripts. Am. J. Hematol. 77:164–166, 2004. © 2004 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom